Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $506.57 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Allovir Inc had its IPO on 2020-07-30 under the ticker symbol ALVR.
The company operates in the Healthcare sector and Biotechnology industry. Allovir Inc has a staff strength of 106 employees.
Shares of Allovir Inc opened at $4.64 at the start of the last trading session i.e. 2023-03-21.
The stocks traded within a range of $4.64 - $4.95, and closed at $4.88.
This is a +7.25% increase from the previous day's closing price.
A total volume of 93,548 shares were traded at the close of the day’s session.
In the last one week, shares of Allovir Inc have increased by +3.83%.
Allovir Inc's Key Ratios
Allovir Inc has a market cap of $506.57 million, indicating a price to book ratio of 2.465 and a price to sales ratio of 0.
In the last 12-months Allovir Inc’s revenue was $0 with a gross profit of $165000 and an EBITDA of $-170479008. The EBITDA ratio measures Allovir Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Allovir Inc’s operating margin was 0% while its return on assets stood at -37.97% with a return of equity of -75.02%.
In Q4, Allovir Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Allovir Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-1.96 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Allovir Inc’s profitability.
Allovir Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -2.0543. Its price to sales ratio in the trailing 12-months stood at 0.
Allovir Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $277.08 million
- Total Liabilities
- $24.34 million
- Operating Cash Flow
- $13.54 million
- Capital Expenditure
- Dividend Payout Ratio
Allovir Inc ended 2023 with $277.08 million in total assets and $0 in total liabilities. Its intangible assets were valued at $277.08 million while shareholder equity stood at $224.52 million.
Allovir Inc ended 2023 with $0 in deferred long-term liabilities, $24.34 million in other current liabilities, 9000.00 in common stock, $-465775000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $106.09 million and cash and short-term investments were $233.80 million. The company’s total short-term debt was $7,165,000 while long-term debt stood at $0.
Allovir Inc’s total current assets stands at $243.05 million while long-term investments were $0 and short-term investments were $127.70 million. Its net receivables were $157000.00 compared to accounts payable of $3.00 million and inventory worth $0.
In 2023, Allovir Inc's operating cash flow was $13.54 million while its capital expenditure stood at $0.
Comparatively, Allovir Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Allovir Inc stock is currently trading at $4.88 per share. It touched a 52-week high of $10.29 and a 52-week low of $10.29. Analysts tracking the stock have a 12-month average target price of $22.
Its 50-day moving average was $5.8 and 200-day moving average was $6.41 The short ratio stood at 18.79 indicating a short percent outstanding of 0%.
Around 4986.3% of the company’s stock are held by insiders while 4063.9% are held by institutions.
Frequently Asked Questions About Allovir Inc
Similar Industry Stocks (Biotechnology)
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.